This 2020 prospective, comparative, non-randomized, open-label study aimed to compare the efficacy and safety of ossein-hydroxyapatite complex (OHC) versus calcium carbonate (CC) for preventing bone loss during perimenopause in current clinical practice. 851 perimenopausal women with basal bone mineral density (BMD) T-score ≥-2 standard deviations (SDs). Participants received either OHC (712 mg calcium/day) or CC (1000 mg calcium/day) over 3 years. OHC showed greater efficacy and tolerability than CC for bone loss prevention in perimenopausal women in real-world practice.
Castelo-Branco C, Cancelo Hidalgo MJ, Palacios S, Ciria-Recasens M, Fernández-Pareja A, Carbonell-Abella C, Manasanch J, Haya-Palazuelos J. Efficacy and safety of ossein-hydroxyapatite complex versus calcium carbonate to prevent bone loss. Climacteric. 2020 Jun;23(3):252-258. doi: 10.1080/13697137.2019.1685488. Epub 2019 Nov 21. PMID: 31747785.